U.S. markets closed
  • S&P 500

    3,901.36
    +0.57 (+0.01%)
     
  • Dow 30

    31,261.90
    +8.77 (+0.03%)
     
  • Nasdaq

    11,354.62
    -33.88 (-0.30%)
     
  • Russell 2000

    1,773.27
    -2.96 (-0.17%)
     
  • Crude Oil

    112.70
    +0.49 (+0.44%)
     
  • Gold

    1,845.10
    +3.90 (+0.21%)
     
  • Silver

    21.87
    -0.03 (-0.13%)
     
  • EUR/USD

    1.0562
    -0.0026 (-0.24%)
     
  • 10-Yr Bond

    2.7870
    -0.0680 (-2.38%)
     
  • GBP/USD

    1.2495
    +0.0020 (+0.16%)
     
  • USD/JPY

    127.8500
    +0.0560 (+0.04%)
     
  • BTC-USD

    29,406.85
    +88.10 (+0.30%)
     
  • CMC Crypto 200

    650.34
    -23.03 (-3.42%)
     
  • FTSE 100

    7,389.98
    +87.24 (+1.19%)
     
  • Nikkei 225

    26,739.03
    +336.19 (+1.27%)
     

Bionano Genomics: Q4 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Bionano Genomics (NASDAQ:BNGO) rose in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share increased 82.61% year over year to ($0.04), which beat the estimate of ($0.05).

Revenue of $3,990,000 up by 43.06% from the same period last year, which beat the estimate of $3,500,000.

Guidance

Bionano Genomics hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Mar 23, 2021

View more earnings on BNGO

Time: 04:30 PM

ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1438152&tp_key=1a103232b0

Price Action

Company's 52-week high was at $15.69

52-week low: $0.25

Price action over last quarter: Up 1580.17%

Company Overview

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.